Tarsus Pharmaceuticals (NASDAQ:TARS) Raised to Hold at Zacks Research

Posted by George Bondi on Oct 15th, 2026

Tarsus Pharmaceuticals (NASDAQ:TARS – Get Free Report) was upgraded by analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued to investors on Tuesday, Zacks reports.

TARS has been the topic of a number of other reports. HC Wainwright reaffirmed a “buy” rating and issued a $88.00 price target on shares of Tarsus Pharmaceuticals in a research note on Thursday, July 9th. Barclays began coverage on Tarsus Pharmaceuticals in a report on Wednesday, September 16th. They issued an “overweight” rating and a $110.00 price objective on the stock. Wall Street Zen lowered Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Guggenheim cut their price objective on Tarsus Pharmaceuticals from $90.00 to $89.00 and set a “buy” rating for the company in a research note on Tuesday, July 21st. Finally, Mizuho reduced their target price on Tarsus Pharmaceuticals from $100.00 to $98.00 and set an “outperform” rating for the company in a report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $100.86.

Get Our Latest Research Report on Tarsus Pharmaceuticals

Tarsus Pharmaceuticals Price Performance

Tarsus Pharmaceuticals stock opened at $72.29 on Tuesday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.17 and a current ratio of 3.20. The company’s fifty day moving average price is $75.17 and its 200 day moving average price is $67.38. The stock has a market capitalization of $3.17 billion, a P/E ratio of -66.32 and a beta of 0.44. Tarsus Pharmaceuticals has a 1 year low of $53.89 and a 1 year high of $91.53.

Tarsus Pharmaceuticals (NASDAQ:TARS – Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.24). The company had revenue of $173.91 million during the quarter, compared to analyst estimates of $169.65 million. Tarsus Pharmaceuticals had a negative net margin of 7.67% and a negative return on equity of 13.53%. As a group, equities research analysts anticipate that Tarsus Pharmaceuticals will post -4.25 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director William Link, PhD sold 12,500 shares of the company’s stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $78.38, for a total transaction of $979,750.00. Following the completion of the sale, the director owned 94,487 shares of the company’s stock, valued at $7,405,891.06. This represents a 11.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Elizabeth Lin sold 3,180 shares of the company’s stock in a transaction on Friday, September 4th. The stock was sold at an average price of $87.50, for a total transaction of $278,250.00. Following the sale, the insider directly owned 1,590 shares of the company’s stock, valued at $139,125. The trade was a 66.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 48,031 shares of company stock valued at $4,004,227 in the last 90 days. 9.64% of the stock is owned by insiders.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of TARS. Hsbc Holdings PLC boosted its holdings in shares of Tarsus Pharmaceuticals by 295.0% during the 2nd quarter. Hsbc Holdings PLC now owns 38,090 shares of the company’s stock worth $2,429,000 after purchasing an additional 28,447 shares during the last quarter. Bank of New York Mellon Corp purchased a new stake in shares of Tarsus Pharmaceuticals in the second quarter valued at approximately $7,204,000. Bank of America Corp DE grew its position in shares of Tarsus Pharmaceuticals by 57.5% in the first quarter. Bank of America Corp DE now owns 1,194,377 shares of the company’s stock valued at $83,786,000 after purchasing an additional 436,271 shares in the last quarter. TimesSquare Capital Management LLC purchased a new stake in shares of Tarsus Pharmaceuticals in the second quarter valued at approximately $23,249,000. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Tarsus Pharmaceuticals in the second quarter valued at approximately $5,726,000. 90.01% of the stock is currently owned by institutional investors and hedge funds.

Tarsus Pharmaceuticals Company Profile

(Get Free Report)

Tarsus Pharmaceuticals, Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for diseases and conditions affecting the eye. The company concentrates on areas of significant unmet need in ophthalmology and aims to address conditions that can affect ocular health, comfort and vision.

Tarsus’ primary product is XDEMVY (lotilaner ophthalmic solution) 0.25%, an eye drop approved by the U.S. Food and Drug Administration in 2023 for the treatment of Demodex blepharitis.